ENXTAM:PHARMBiotechs
Assessing Pharming Group (ENXTAM:PHARM) Valuation After Return To Full Year Profitability
Why Pharming Group’s latest earnings drew investor attention
Pharming Group (ENXTAM:PHARM) has come into focus after reporting fourth quarter and full year 2025 earnings, with the company moving from a full year net loss to a net profit.
Investors are weighing how sales of US$106.5 million in the quarter and US$376.13 million for 2025, together with net income of US$5.3 million for the quarter and US$2.85 million for the year, might influence sentiment toward the stock.
See our latest...